Clinical trial registry record

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated November 18, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02305238
Last registry update
November 18, 2023
Status
Completed
Phase
Phase 4
Sponsor
Bayer
Enrollment
288
Countries
Japan
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
288
Population
ALL · 50 Years
Duration
2014-12-19 to 2017-12-20
Intervention
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Comparator
Not reported
Outcomes measured
Mean Change From Baseline in BCVA at Week 52 — Baseline and Week 52; Percentage of Participants Who Maintained Vision at Week 52 — Week 52; Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52 — Baseline and Week…; Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52 — Baseline and week 52; Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52 — Week 52
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON